A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo

Journal of Autoimmunity

Volumn 22, Issue 3, 2004, Pages 217-225

  Pierangeli, Silvia S ^a   Blank, Miri ^b   Liu, Xiaowei ^a   Espinola, Ricardo ^a   Fridkin, Mati ^c   Ostertag, Mariano Vega ^a   Roye Green, Karen ^a   Harris, E Nigel ^a   Shoenfeld, Yehuda ^b  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Anti beta 2 glycoprotein I; Antiphospholipid antibodies; Antiphospholipid syndrome; Bacteria; Peptides; Thrombosis; Viruses

Indexed keywords

BACTERIAL ANTIGEN; PHOSPHOLIPID ANTIBODY;

ADENOVIRUS; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMORAL VEIN; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; POLYOMA VIRUS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHISTOSOMA MANSONI; THROMBOSIS; THROMBUS; YERSINIA PSEUDOTUBERCULOSIS;

ANTIGENS, BACTERIAL; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION; CARDIOLIPINS; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEPTIDE FRAGMENTS; PHOSPHOLIPIDS; SERUM;

EID: 1642277857     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaut.2004.01.002     Document Type: Article

References (57)

1. Harris E.N. Syndrome of the Black Swan. Br J Rheumatol. 26:1987;324-326.
2. Kamashta M.A., Hughes G.R.V. Antiphospholipid antibodies: a marker for thrombosis and recurrent abortion. Clin Rev Allergy Immunol. 12:1994;287-296.
3. Harris E.N., Pierangeli S.S. Antiphospholipd antibodies and the antiphospholipid syndrome. Springer Semin Immunopathol. 16:1994;223-225.
4. Pierangeli S.S., Barker J.H., Stikovac D., Ackerman D., Anderson G., Barquinero J., et al. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemost. 71:1994;670-674.
5. Pierangeli S.S., Liu X.W., Barker J.H., Anderson G., Harris E.N. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost. 74:1995;1362-1367.
6. Pierangeli S.S., Harris E.N. In vivo models of thrombosis for the antiphospholipid syndrome. Lupus. 5:1996;451-455.
7. Olee T., Pierangeli S.S., Handley H.H., Le D.T., Wei X.m., Lai C.J., et al. A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. Proc Natl Acad Sci U S A. 93:1996;8606-8611.
8. Bakimer R., Fishman P., Blank M., Sredni B., Djaletti M., Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest. 89:1992;1558-1563.
9. Branch D.W., Dudley D.J., Mitchell M.D., Creighton K.A., Abbot T.M., Hammond E.H., et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol. 163:1990;210-216.
10. Gharavi A.E., Pierangeli S.S., Colden M., Liu X., Espinola R.G., Harris E.N. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol. 163:1999;2922-2927.
11. 2glycoprotein I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest. 106:(6):2002;797-804.
12. Gharavi A.E., Pierangeli S.S., Espinola R.G., Liu X., Colden-Stanfield M., Harris E.N. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum. 46:(2):2002;545-552.
13. Gharavi A.E., Vega-Ostertag M., Espinola R.G., Liu X., Cole L., Cox N.T., et al. Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus. 2003;. in press.
14. Visvanathan S., Scott J.K., Hwang K.K., Banares M., Grossman J.M., Merrill J.T., et al. Identification and characterization of a peptide mimetc that may detect a species of disease-associated anticardiolipin antibodies in patients with antiphospholipid syndrome. Arthritis Rheum. 48:(3):2003;737-745.
15. Blank M., Shoenfeld Y., Cabilly S., Heldman Y., Fridkin M., Katchalski-Katzer E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci U S A. 96:1999;5164-5168.
16. Wilson W., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., et al. International consensus statement on preliminary classification criteria for definite APS: report of an international workshop. Arthritis Rheum. 42:(7):1999;1309-1311.
17. Harris E.N., Gharavi A.E., Boey M.L., Patel M.B., Macworth C.G., Loizou S., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 2:1983;1211-1214.
18. 2glycoprotein I. Br J Haematol. 87:1994;548-554.
19. Pierangeli S.S., Colden-Stanfield M., Liu X., Barker J.H., Anderson G.L., Harris E.N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 163:(99):1999;1997-2002.
20. Pierangeli S.S., Espinola R.G., Liu X., Harris E.N. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1 and P-selectin. Circ Res. 88:(2):2001;245-250.
21. McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 87:1990;4120-4124.
22. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Suzuki T., Sumida T., et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol. 148:1992;3885-3891.
23. 2glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 79:(2):1992;457-462.
24. 2glycoprotein I and preserved during species' evolution. J Immunol. 157:(12):1996;5732-5738.
25. Rouey R.A., Hoffman M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet. 350:(9090):1997;1491-1493.
26. 2glycoprotein I. Biochem J. 277:1991;387.
27. 2glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol. 155:1995;1629.
28. 2GPI. Proc Natl Acad Sci U S A. 95:1998;15542.
29. 2GPI in antibody binding. J Immunol. 160:1998;3917.
30. 2Glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood. 87:(8):1996;3262-3270.
31. 2glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol. 169:2002;7097-7103.
32. Arnout J., Spitz B., Wittervronge C., Vanrusselt M., van Assche A., Vermylen J. High-dose intravenous immunoglobulin treatment of a pregnant patient with antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb Haemost. 71:1994;741-747.
33. Clark A.L., Branch D.W., Silver R.M., Harris E.N., Pierangeli S.S., Spinatto J.A. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstet Gynecol. 93:(3):1999;437-441.
34. Krause I., Blank M., Kopolovic J., Afek A., Goldberg I., Tomer Y., et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol. 22:(6):1995;1068-1074.
35. Pierangeli S.S., Espinola R.G., Liu X., Harris E.N., Salmon J.E. Identification of an Fcγ receptor-independent mechanisms bywhich intravenous-immunoglobulin ameliorates antiphospholipid-antibody-induced thrombogenic phenotype. Arthritis Rheum. 44:(4):2001;867-883.
36. Puri V., Bookman A., Yeo E., Cameron R., Heathcote E.J. Antiphospholipid antibody syndrome associated with hepatitis C infection. J Rheumatol. 26:1999;509-510.
37. Hayem G., Kassis N., Nicaise P., Bouvet P., Andremont A., Labarre C., et al. Systemic lupus erythematosus-associated catastrophic antiphospholipid syndrome occurring after typhoid fever: a possible role of Salmonella lipopolysaccharide in the occurrence of diffuse vasculopathy-coagulopathy. Arthritis Rheum. 42:1999;1056-1061.
38. Shoenfeld Y., Blank M., Krause I. The relationship of anti-phospholipid antibodies to infections - do they bind to infecting agents or may they even be induced by them. Clin Exp Rheumatol. 18:2000;431-432.
39. Costello P.B., Green F.A. Reactivity patterns of human anticardiolipin and other antiphospholipid antibodies in syphilitic sera. Infect Immun. 51:1986;771-775.
40. Durupt S., Rosselli S., Manchin J., Lopez M. Presence of antiphospholipid antibodies in "legionnaires disease" Presse Med. 25:(34):1996;1649-1659.
41. Santiago M.B., Cossemelli W., Tuma M.F., Oliveira R.M. Anticardiolipin antibodies in infectious diseases. Clin Rheumatol. 8:(1):1989;23-28.
42. Mackworth-Young C.G., Harris E.N., Steere A.C., Rizvi F., Malawista S.E., Hughes G.R.V., et al. Anticardiolipin antibodies in lyme disease. Arthritis Rheum. 31:1988;1052-1057.
43. Labarca J.A., Rabagliatti R.M., Radrigan F.J., Rojas O.O., Perez C.M., Ferres M.V., et al. Antiphospholipid syndrome associated with cytomegalovirus infection. A case report and review. Clin Infect Dis. 24:(2):1997;197-200.
44. Poux J.M., Jauberteau M.O., Boudet R., Leroux-Robert C., Loizou F. Transient lupus anticoagulant induced by Epstein-Barr virus infections. Blood Coagul Fibrinolysis. 2:(6):1991;771-774.
45. 2glycoprotein I-dependent anticardiolipin antibodies as a risk factor for reactions in borderline leprosy patients. Int J Lepr Other Mycobact Dis. 66:(3):1998;387-388.
46. Galvez J., Martin I., Medino D., Pujol E. Thrombophlebitis in a patiens with acute Q fever and anticardiolipin antibodies. Med Clin (Barc). 108:(10):1995;396-397.
47. 2glycoprotein I in HIV-seropositive patients: relationship with endothelial activation and antimalonic dialdehyde antibodies. Eur J Clin Invest. 28:1998;115-122.
48. Manco-Johnson M.J., Nuss R., Key N., Moertel C., Jacobson K., Meech S., et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpira fulminans or thrombosis. J Pediatr. 128:(3):1996;319-323.
49. 2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy. Lupus. 3:1994;515-521.
50. 2-glycoprotein I-dependent anticardiolipin antibodies as risk factor for reactions in borderline leprosy patients. Int J Lepr Other Mycobact Dis. 66:1998;387-388.
51. Loizou S., Cazabon J.K., Walport M.J., Tait D., So A.K. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum. 40:1997;103-108.
52. Giordano P., Galli M., Del Vecchio G.C., Altomare M., Norbis F., Ruggeri L., et al. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassaemia. Br J Haematol. 102:1998;903-906.
53. Uthman I., Tabbrah Z., Gharavi A.E. Hughes syndrome associated with cytomegalovirus infection. Lupus. 8:(9):1999;775-777.
54. Ray S.K., Putterman C., Diamond B. Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc Natl Acad Sci U S A. 93:1996;2019-2024.
55. El-Roeiy A., Gross W.L., Luedemann J., Isenberg D.A., Shoenfeld Y. Preferential secretion of a common anti-DNA idiotype (16/6d) and anti-polynyucleotide antibodies by normal mononuclear cells following stimulation with Klebsiella pneumoniae. Immunol Lett. 12:1986;313-319.
56. Grayel A., Solomon A., Aranow C., Diamond B. Antibodies elicited by pneumococcal antigens bear anti-DNA associated idiotype. J Clin Invest. 87:1991;842-846.
57. Kowal C., Weinstein A., Diamond B. Molecular mimicry between bacterial and self antigen in a patient with systemic lupus erythematosus. Eur J Immunol. 29:1999;1901-1911.